Pulse Biosciences wins FDA approval for AF study using nsPFA technology
September 9, 2025
The trial will evaluate the effectiveness of the nsPFA cardiac surgical system during concurrent surgical procedures.
The trial will evaluate the effectiveness of the nsPFA cardiac surgical system during concurrent surgical procedures.
The test detects amyloid plaques, abnormal brain protein deposits linked to cognitive impairment and a key indicator of Alzheimer’s.
Neurescue’s device is claimed to be the first catheter to have received a CE mark for addressing non-shockable cardiac arrest.
The company has completed registration and certification for its total disc replacement products, which are now CE-marked.
Glioblastoma is a devastatingly effective brain cancer. Doctors can cut it out or blast it with radiation, but that only buys time. The cancer has an insidious ability to hide enough tumor cells in tissue around the tumor to allow it to return as deadly as ever.
Johnson & Johnson (NYSE:JNJ) announced today that the FDA approved Inlexzo, its gemcitabine intravesical drug delivery system.
SEOUL, South Korea, Sept. 9, 2025 /PRNewswire/ — Patients who suffer from chronic conditions often require continuous injections of drugs, which is quite painful and often inconvenient.
SAN FRANCISCO, Sept. 9, 2025 /PRNewswire/ — Willow Innovations, Inc. (Willow), the Femtech leader and inventor of the first fully in-bra wearable breast pump, is once again revolutionizing the pumping experience with the launch of its newest innovation.
CAMPBELL, Calif., Sept. 9, 2025 /PRNewswire/ — Vivalink, a leading provider of digital healthcare solutions, today announced the commercial release of its new wearable ECG sensor adhesive that improves the detection of p-waves during ambulatory cardiac monitoring
Neurescue announced today that it received CE mark approval for its device designed to treat non-shockable cardiac arrest.